PMID- 35965181
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20220915
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 83
IP  - 10
DP  - 2022 Oct
TI  - Donor selection based on NK alloreactivity for patients with hematological 
      malignancies.
PG  - 695-703
LID - S0198-8859(22)00141-0 [pii]
LID - 10.1016/j.humimm.2022.07.006 [doi]
AB  - Natural killer (NK) cells are an important defender against infections and 
      tumors. Their function is regulated by the balance of inhibitory and activating 
      receptors. Among all inhibitory NK receptors: killer immunoglobulin-like 
      receptors (KIR) and CD94/NKG2A recognize human leukocyte antigen (HLA) Class I 
      molecules, allowing NK cells to be 'licensed' to avoid autoreactivity, but be 
      fully functional at the same time. Licensed NK cells can target malignant cells 
      with altered or downregulated/missing 'self' antigens. NK cell attacking 
      malignant cells is one of the mechanisms of graft-versus-leukemia (GVL) effect. 
      Numerous studies have demonstrated that NK cells improve hematopoietic stem cell 
      transplantation (HCT) survival by reducing relapse mortality through GVL effect. 
      Therapeutic strategies, such as adoptive alloreactive NK cell transfer, CAR-NK 
      cells, antibodies against NKG2A and KIR2DL1-3, have been utilized to treat 
      hematological malignancies in HCT. In this review, NK cell functions, NK cell 
      receptors and ligands, as well as common alloreactive NK donor selection 
      algorithms for patients with hematological malignancies in the setting of HCT are 
      discussed. The goal of this review is to provide insights on the controversial 
      results and provide better understanding and resources on how to perform 
      alloreactive donor NK cell selection in HCT.
CI  - Copyright (c) 2022 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Jennifer Zhang, Qiuheng
AU  - Jennifer Zhang Q
AD  - UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, 
      David Geffen School of Medicine, University of California, Los Angeles 90095, 
      USA. Electronic address: jqzhang@mednet.ucla.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220811
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Donor Selection
MH  - *Hematologic Neoplasms/therapy
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - Humans
MH  - Killer Cells, Natural
MH  - Receptors, KIR/genetics
OTO - NOTNLM
OT  - GVHD
OT  - GVL
OT  - Hematopoietic stem cell transplant
OT  - KIR
OT  - Natural killer cell
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/08/15 06:00
MHDA- 2022/09/16 06:00
CRDT- 2022/08/14 22:05
PHST- 2022/05/31 00:00 [received]
PHST- 2022/07/12 00:00 [revised]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/08/15 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
PHST- 2022/08/14 22:05 [entrez]
AID - S0198-8859(22)00141-0 [pii]
AID - 10.1016/j.humimm.2022.07.006 [doi]
PST - ppublish
SO  - Hum Immunol. 2022 Oct;83(10):695-703. doi: 10.1016/j.humimm.2022.07.006. Epub 
      2022 Aug 11.